SAIMO(02571): The public shareholding is about 22.58%

22:44 16/01/2026

Sime Technology (02571) announced that as of the date of this announcement, the company's public shareholding is approximately 22.58%, which is below the minimum percentage of 25% required by Rule 19A.28B(1)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The shortfall is due to 3.2262 million shares (approximately 2.42% of the total number of shares issued by the company as of the date of this announcement) held by China International Trust (Hong Kong) Co., Ltd. (China International Trust), which is a qualified participant in the 2025 H-share incentive trust plan adopted by the company on June 17, 2025, as a non-core related person. These shares have not been awarded to the participants and are therefore not considered part of the public shareholding.

SAIMO (02571) announces that as of the date of this announcement, the company's public shareholding is approximately 22.58%, which is below the minimum percentage of 25% as required by Rule 19A.28B(1)(a) of the Listing Rules of The Stock Exchange of Hong Kong Limited. The shortfall is due to 3.22 million shares (approximately 2.42% of the total issued shares of the company as of the date of this announcement) held by Industrial and Commercial Bank International Trust Company Limited (ICBC International Trust, the trustee of the 2025 H-share incentive trust plan adopted by the company on June 17, 2025) as a qualified participant that is not a non-core connected person. These shares have not been allocated to the participants and therefore are not considered as part of the public shareholding.

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.

Yinbang Clad Material (300337.SZ) is planning to register and issue medium-term notes.

HK Stock Market Move | NATURAL FOOD IH(01837) continues to rise by over 5%, offline channel business significantly grows, with annual net profit increasing by approximately 40% compared to the previous year.

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.

Yinbang Clad Material (300337.SZ) is planning to register and issue medium-term notes.